GlassScriptPhysician profile
George Blair Smallfield
NPI 1770667651
$4,194.06
in general payments reported to CMS, 2019-2025
26 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $94.32 · 2021: $218 · 2022: $35.49 · 2023: $225 · 2024: $1,236 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464 · Education: $35.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,464.19 |
| Education | $35.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,087.08 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Medtronic, INC. | $412.63 | 2021-2024 | Interstim, Endoflip |
| Qol Medical, LLC | $402.46 | 2024-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $393.42 | 2024-2025 | Tremfya, Stelara |
| Genzyme Corporation | $313.48 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.70 | 2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $199.71 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $165.82 | 2024-2025 | Omvoh |
| Pfizer INC. | $152.04 | 2020-2025 | |
| Boston Scientific Corporation | $148.85 | 2019-2022 | |
| Endogastric Solutions, INC | $132.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.40 | 2023-2025 | Xifaxan, Trulance |
| Steris Corporation | $96.49 | 2024 | |
| Merck Sharp & Dohme LLC | $64.39 | 2023-2024 | Dificid |
| Ardelyx, INC. | $48.05 | 2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $35.31 | 2024 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $27.83 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $22.80 | 2024 | |
| Intercept Pharmaceuticals, INC. | $21.60 | 2024 | |
| Pharmacosmos Therapeutics INC. | $21.45 | 2024 | Monoferric |
| Lucid Diagnostics INC. | $21.21 | 2024 | |
| Aimmune Therapeutics, INC. | $21.15 | 2025 | Zenpep |
| Covidien LP | $19.23 | 2019 | |
| Novo Nordisk INC | $17.66 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $15.01 | 2024 | Sutab, Suflave |
| Conmed Corporation | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Smallfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.